네테라 (NTRA) 주가

네테라(NTRA)는 NASDAQ에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $361.62 (-1.28%), 시가총액 $29.23B, 52주 최저~최고 $133.66 ~ $254.40.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-g

핵심 지표

• 현재가: $361.62 (-1.28%)
• 시가총액: $29.23B
• 52주 최저~최고: $133.66 ~ $254.40
• 섹터: Healthcare
• 산업: Diagnostics & Research
• 거래소: NASDAQ

네테라의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

네테라 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.4762

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 16.54
• 순이익률: -0.09%
• 영업이익률: -0.12%

자주 묻는 질문